• ELP4, ZEB2, and TCF7L2 in Ischemic Stroke

  2026-08-17

  The reference study identifies TCF7L2 as a driver of pro-inflammatory microglial polarization after ischemic stroke and defines opposing upstream control by ELP4 and ZEB2. Its combination of ischemia models, chromatin and ubiquitination analyses, and pharmacological TLR4 inhibition provides a mechanistic framework for studying inflammatory signal pathway suppression in stroke-related neuroinflammation research.

• β-Amanitin: From Pol II Probe to Assay Design

  2026-08-17

  β-Amanitin is more than a transcription inhibitor: it is a controlled perturbation tool for linking RNA polymerase II activity to assay readouts. This guide connects mechanistic experiment design with emerging amatoxin biosensing while clarifying practical handling and interpretation limits.

• SB525334 in TGF-beta1 Receptor Signaling

  2026-08-16

  SB525334 provides a selective way to test whether ALK5 signaling drives profibrotic, renal, or wound-repair phenotypes. This workflow connects precise Smad2/3 readouts with the bone-transport diabetic foot ulcer findings while clearly separating validated evidence from proposed assay extensions.

• MAPK10–KRT16 Signaling Restrains NSCLC Metastasis

  2026-08-15

  The reference study identifies a phosphorylation-dependent MAPK10–KRT16–RNF213 pathway that limits non-small cell lung cancer metastasis. Its combination of mechanistic, in vivo, and clinical evidence suggests that KRT16 turnover may be more informative than KRT16 transcription alone when evaluating metastatic risk.

• Cycloastragenol Protects Against GIONFH Bone Loss

  2026-08-14

  This in vivo study identifies osteoclast overactivity as a modifiable component of glucocorticoid-induced osteonecrosis of the femoral head and shows that cycloastragenol preserves femoral-head structure in methylprednisolone-treated rats. Micro-CT, angiography, histology, gene-expression analysis, and protein assays together support cycloastragenol as a candidate hip-preservation strategy, while its clinical value remains to be established.

• (5Z)-7-Oxozeaenol: A TAK1 Assay Strategy

  2026-08-14

  (5Z)-7-Oxozeaenol is a selective TAK1 inhibitor for dissecting inflammatory signaling and metabolic-stress adaptation. This article translates AMPK–SQSTM1 feedback-loop findings into a practical, causally resolved assay strategy.

• Ac-YVAD-CMK: A Precision Lens on Liver Inflammation

  2026-08-13

  TMEM16F-dependent membrane repair in Kupffer cells reveals why inflammatory cell death must be interpreted in context. This thought-leadership guide positions Ac-YVAD-CMK as a mechanistically focused probe for separating caspase-1-driven cytokine maturation and pyroptosis from membrane injury during liver infection research.

• MCC950 sodium: Practical NLRP3 Assay Workflows

  2026-08-13

  MCC950 sodium provides a selective way to test whether NLRP3 drives oxidative-stress pyroptosis rather than relying on pleiotropic anti-inflammatory compounds alone. This guide translates endothelial-cell findings into reproducible macrophage, PBMC, and disease-model workflows with practical controls and troubleshooting.

• MCC950 sodium in Endotoxemia Workflows

  2026-08-12

  MCC950 sodium enables selective testing of NLRP3 contributions to cytokine release, extracellular-vesicle tissue factor, and coagulation during endotoxemia. This workflow-centered guide shows how to pair pharmacological inhibition with time-resolved inflammatory and hemostatic readouts while avoiding common interpretation errors.

• BIBR 1532 Workflows for Telomerase Research

  2026-08-12

  BIBR 1532 enables direct, non-nucleosidic telomerase inhibition studies alongside proliferation, transcriptional, and apoptosis readouts. This workflow distinguishes hTERT-dependent effects from the DNA-damage and telomere-attrition mechanisms reported for CF10 plus EdU combinations.

• Indazole Glucagon Receptor Antagonists: Study Insights

  2026-08-11

  This 2015 Bioorganic & Medicinal Chemistry Letters study describes indazole- and indole-based glucagon receptor antagonists derived from the earlier MK-0893 program. Its structure–activity relationship work identified compounds with strong in vitro activity, favorable rat pharmacokinetics, and oral glucose-lowering activity for GRA 16d in glucagon receptor humanized mouse models.

• Ibrexafungerp: Antifungal Research Workflows

  2026-08-11

  Ibrexafungerp, also known as MK 3118, supports research on resistant Candida through a non-competitive glucan synthase mechanism and oral dosing potential. This guide connects broth microdilution, acidic-pH testing, and delayed-treatment animal models with practical optimization and troubleshooting steps.

• Methylprednisolone in Reliable Cell Assays

  2026-08-10

  This scenario-based guide shows how Methylprednisolone, SKU A4233, can be incorporated into cell viability, proliferation, cytotoxicity, and inflammatory-response workflows without confusing metabolic effects with cell loss. It connects product handling data with translational glucocorticoid research and practical controls for more interpretable experiments.

• TMEM16F in Kupffer Cells Protects Against Listeria

  2026-08-09

  The reference study identifies Kupffer cell-expressed TMEM16F as a critical, cell-specific determinant of protection against Listeria monocytogenes. By linking lipid scrambling and plasma-membrane repair to liver inflammation, tissue injury, and metabolic disruption, it establishes a mechanistic framework for studying host defense beyond lymphocyte-centered models.

• MCC950 sodium: Reliable NLRP3 Assay Workflows

  2026-08-08

  This scenario-based guide explains how MCC950 sodium supports interpretable viability, cytotoxicity, and inflammasome experiments without confusing metabolic rescue with pathway-specific inhibition. It also outlines practical handling and vendor-selection considerations for SKU B7946 in inflammatory disease research.

586 records 10/40 page Previous Next First page 上5页 678910 下5页 Last page